drugset / Trial / NCT04284995
A Phase 2 Open Label Study to Assess the PK/PD Properties of RUC-4 in Patients With a ST-elevation Myocardial Infarction
Phase 2
Completed
27 enrolled
CeleCor Therapeutics
Diagram B.V. · collabSt. Antonius Hospital · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
RUC-4 is a novel, promising and fast acting (5-15 minutes) αIIbβ3 receptor antagonist with a high-grade inhibition of platelet aggregation (≥80%) shortly after subcutaneous administration. This study is designed to extend the findings in CEL-01 to patients with ST-elevation myocardial Infarction (STEMI) presenting to the cardiac catheterization laboratory with planned coronary angioplasty.
Timeline
- Start
- 2020-06-02
- Primary completion
- 2020-11-08
- Completion
- 2020-12-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | zalunfiban | Small molecule | 0.075 mg/kg | Subcutaneous |